ES2188783T3 - Empleo de una tienotriazolodiazepina para aumentar los niveles de apolipoproteina a-i. - Google Patents

Empleo de una tienotriazolodiazepina para aumentar los niveles de apolipoproteina a-i.

Info

Publication number
ES2188783T3
ES2188783T3 ES96930137T ES96930137T ES2188783T3 ES 2188783 T3 ES2188783 T3 ES 2188783T3 ES 96930137 T ES96930137 T ES 96930137T ES 96930137 T ES96930137 T ES 96930137T ES 2188783 T3 ES2188783 T3 ES 2188783T3
Authority
ES
Spain
Prior art keywords
apolipoprotein
levels
tienotriazolodiazepin
increase
tienol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96930137T
Other languages
English (en)
Spanish (es)
Inventor
Herman Kempen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2188783T3 publication Critical patent/ES2188783T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
ES96930137T 1995-09-09 1996-08-30 Empleo de una tienotriazolodiazepina para aumentar los niveles de apolipoproteina a-i. Expired - Lifetime ES2188783T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP95114163 1995-09-09

Publications (1)

Publication Number Publication Date
ES2188783T3 true ES2188783T3 (es) 2003-07-01

Family

ID=8219597

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96930137T Expired - Lifetime ES2188783T3 (es) 1995-09-09 1996-08-30 Empleo de una tienotriazolodiazepina para aumentar los niveles de apolipoproteina a-i.

Country Status (14)

Country Link
US (1) US5854238A (https=)
EP (1) EP0853480B1 (https=)
JP (1) JPH11512107A (https=)
KR (1) KR19990044460A (https=)
CN (1) CN1101680C (https=)
AT (1) ATE230600T1 (https=)
AU (1) AU725249B2 (https=)
BR (1) BR9610390A (https=)
CA (1) CA2230477A1 (https=)
DE (1) DE69625696T2 (https=)
DK (1) DK0853480T3 (https=)
ES (1) ES2188783T3 (https=)
TR (1) TR199800406T1 (https=)
WO (1) WO1997009048A1 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6518412B1 (en) * 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) * 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6253569B1 (en) * 1999-05-07 2001-07-03 James J. Hall Portable storage unit for game animals
US7723303B2 (en) 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US7199102B2 (en) 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US7166578B2 (en) 2000-08-24 2007-01-23 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7144862B2 (en) 2000-08-24 2006-12-05 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US7429593B2 (en) 2001-09-14 2008-09-30 Shionogi & Co., Ltd. Utilities of amide compounds
US8124625B2 (en) 2001-09-14 2012-02-28 Shionogi & Co., Ltd. Method of enhancing the expression of apolipoprotein AI using olefin derivatives
EP2168576A3 (en) 2001-09-14 2010-05-26 Shionogi & Co., Ltd. Tricyclic compounds for treating dyslipidemia and arteriosclerotic diseases
US6930085B2 (en) * 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
KR20070089996A (ko) 2004-12-06 2007-09-04 더 리전트 오브 더 유니버시티 오브 캘리포니아 세동맥의 구조 및 기능의 개선 방법
EP2195331B1 (en) 2007-08-28 2013-11-20 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
WO2009032702A2 (en) 2007-08-28 2009-03-12 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
ES2448567T3 (es) * 2008-10-30 2014-03-14 Circomed Llc Derivados de la tienotriazoldiazepina activos en apo A
PL2902030T3 (pl) 2010-05-14 2017-07-31 Dana-Farber Cancer Institute, Inc. Związki tienotriazolodiazepinowe do leczenia nowotworu
CN103119160B (zh) * 2010-05-14 2016-06-01 达那-法伯癌症研究所 用于调节代谢的组合物和方法
MX354217B (es) 2010-05-14 2018-02-19 Dana Farber Cancer Inst Inc Composiciones y metodos para el tratamiento de leucemia.
EP2571875A4 (en) 2010-05-14 2013-10-30 Dana Farber Cancer Inst Inc CONTRACEPTIVE COMPOSITIONS FOR MEN AND METHODS OF USE THEREOF
US9975896B2 (en) 2013-07-25 2018-05-22 Dana-Farber Cancer Institute, Inc. Inhibitors of transcription factors and uses thereof
RU2016122654A (ru) 2013-11-08 2017-12-14 Дана-Фарбер Кэнсер Инститьют, Инк. Комбинированная терапия злокачественной опухоли с использованием ингибиторов бромодоменового и экстратерминального (вет) белка
EP3099677A4 (en) 2014-01-31 2017-07-26 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
US10793571B2 (en) 2014-01-31 2020-10-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
JP2017506666A (ja) 2014-02-28 2017-03-09 テンシャ セラピューティクス，インコーポレイテッド 高インスリン血症に関連した症状の処置
WO2016018665A1 (en) 2014-07-31 2016-02-04 Uab Research Foundation Apoe mimetic peptides and higher potency to clear plasma cholesterol
CN106793775B (zh) 2014-08-08 2020-06-02 达纳-法伯癌症研究所股份有限公司 二氢碟啶酮衍生物及其用途
CN106715437A (zh) 2014-08-08 2017-05-24 达纳-法伯癌症研究所股份有限公司 二氮杂环庚烷衍生物及其用途
KR20170068597A (ko) 2014-10-27 2017-06-19 텐샤 세러퓨틱스 인코포레이티드 브로모도메인 저해제
WO2016201370A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
RU2018112953A (ru) 2015-09-11 2019-10-14 Дана-Фарбер Кэнсер Инститьют, Инк. Ацетамидтиенотриазолодиазепины и пути их применения
EP3347021A4 (en) 2015-09-11 2019-07-24 Dana-Farber Cancer Institute, Inc. CYANOTHIENOTRIAZOLDIAZEPINE AND USES THEREOF
MX2018006499A (es) 2015-11-25 2018-08-01 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos.
AU2019284971A1 (en) 2018-06-13 2020-12-03 Worg Pharmaceuticals (Zhejiang) Co., Ltd. Preparation of condensed triazepine derivatives and their use as BET inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4155913A (en) * 1973-02-08 1979-05-22 Hoffmann-La Roche Inc. Thienotriazolodiazepine derivatives
PH12303A (en) * 1973-02-08 1979-01-16 Hoffmann La Roche Thienotriazolodiazepine derivatives
JPS50100096A (https=) * 1974-01-08 1975-08-08

Also Published As

Publication number Publication date
JPH11512107A (ja) 1999-10-19
BR9610390A (pt) 1999-07-06
DE69625696D1 (de) 2003-02-13
DE69625696T2 (de) 2003-10-16
DK0853480T3 (da) 2003-05-05
CN1101680C (zh) 2003-02-19
MX9801753A (es) 1998-08-30
CA2230477A1 (en) 1997-03-13
EP0853480B1 (en) 2003-01-08
AU725249B2 (en) 2000-10-12
AU6930396A (en) 1997-03-27
CN1195989A (zh) 1998-10-14
WO1997009048A1 (en) 1997-03-13
EP0853480A1 (en) 1998-07-22
US5854238A (en) 1998-12-29
TR199800406T1 (en) 1998-05-21
KR19990044460A (ko) 1999-06-25
ATE230600T1 (de) 2003-01-15

Similar Documents

Publication Publication Date Title
ES2188783T3 (es) Empleo de una tienotriazolodiazepina para aumentar los niveles de apolipoproteina a-i.
ES2171971T3 (es) Producto limpiador y de tratamiento con almidon.
AR002039A1 (es) Pirido[3.2-e]pirazinonas con efecto antiasmatico, y procedimiento para su preparacion y los medicamentos que los contienen y su preparación
MX9204268A (es) Una composicion para la liberacion prolongada y controlada de substancias medicamentosas y un proceso para preparar la misma.
ES2172670T3 (es) Pirrolpirimidinas y procedimientos para su preparacion.
FI973868A0 (fi) D2-vitamiini- tai D4-vitamiinijohdannaisten käyttö sekundaarisen hyperparatyreoosin hoitoon tarkoitettu lääkkeen valmistuksessa
ES2138622T3 (es) Derivados de mercaptoacetilamido piridazo(1,2-a)(1,2)diazepina utilizados como inhibidores de encefalinasa y eca.
YU51095A (sh) Benzokazolil - i benzotiazolil-oksazo lidinoni
AR042262A2 (es) Uso de 8,9-dihidroestrona para la preparacion de un medicamento para el tratamiento de aterosclerosis
EP0744181A3 (en) Blood chamber
ES2079063T3 (es) Utilizacion de analogos de vitamina d en el tratamiento del acne.
YU1097A (sh) 2-okso i 2-tio-1,2-dihidrohinolinil-oksazolidinoni
MX9301129A (es) Nuevas ciclosporinas y composiciones farmaceuticas que las contienen.
MX9701385A (es) Preparacion de producto combinado para usarse en enfermedades inmunologicas.
ES2170259T3 (es) Empleo de lipidos como agentes auxiliares en la obtencion de formas farmaceuticas solidas segun el procedimiento de extrusion en fusion.
NO964539D0 (no) Kollagen-preparat for kontrollert avgivelse av virkestoffer
ES2181165T3 (es) Uso de un peptido asociado a la latencia para la preparacion de un medicamento para aumentar la curacion de heridas.
ES2124327T3 (es) Derivados de sulfonamida aminometileno como inmunosupresores.
ES2161750T3 (es) Uso de 17alfa-dihidroequilenina para disminuir el nivel de colesterol.
MX9704034A (es) Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso.
AR059965A2 (es) Uso de 8,9-dehidroestrona para la preparacion de un medicamento antioxidante
ES2193248T3 (es) Antraquinonas mono- y disulfosustituidas y su uso para el tratamiento de desordenes de la matriz osea.
ES2086195T3 (es) Nuevos derivados pseudopeptidicos de actividad antagonista de la bradiquinina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
BR0112025A (pt) Prótese dentária, processo para sua fabricação e uso da mesma
ES2175153T3 (es) Uso de inhibidores de colinesterasa para la fabricacion de un medicamento para el tratamiento de la xerostomia.